|Bid||10.300 x 0|
|Ask||10.600 x 0|
|Day's Range||10.310 - 10.550|
|52 Week Range||9.677 - 16.950|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jan 29, 2018 - Feb 2, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||68.00|
Today, I will be analyzing Scancell Holdings plc’s (AIM:SCLP) recent ownership structure, an important but not-so-popular subject among individual investors. Ownership structure of a company has been found to affectRead More...
Scancell Holdings plc (AIM:SCLP), a GBP£39.40M small-cap, is a healthcare company operating in an industry, which has experienced tailwinds from issues such as higher demand driven by an aging populationRead More...
In January, Scancell Holdings Plc. (SCLP.L) announced an important collaboration with the Addario Lung Cancer Medical Institute (ALCMI) and the Addario Lung Cancer Foundation (ALCF). The joint work will help develop Scancell’s second ImmunoBody platform agent SCIB2 for treating non-small cell lung cancer (NSCLC). Lung cancer has the highest death rate of any cancer with an estimated 156,000 deaths in 2017, according to the American Cancer Society. NSCLC comprises the vast majority of this total, with about 85% of new cases. Chemotherapy is less effective in NSCLC and survival rates are generally low compared to other cancer types, further incentivizing the search for alternative therapies including immunotherapy and vaccines. The need for more effective therapies sets the stage for important joint efforts between biotechnology companies and patient-centered organizations.
Scancell Holdings Plc. (SCLP.L) is a UK-based, cancer-focused, biotechnology company developing three vaccine products for skin, lung, breast and ovarian and osteosarcoma. The company has shown exciting promise in its lead immunotherapy candidate, SCIB1, in the treatment of melanoma, which it expects to be particularly useful in combination with checkpoint inhibitors such as Keytruda. The drug is able to stimulate the patient’s own immune system to eradicate tumor cells resulting in a 95% survival rate in the ongoing Phase I/II trial. The company’s pipeline is divided into two vaccine platforms: ImmunoBody and Moditope. The ImmunoBody process works by targeting Fc receptors on the surface of dendritic cells. The mechanism targets these cells using both direct presentation and indirect (cross) presentation. Direct presentation transfers the ImmunoBody DNA into the antigen presenting cell (APC) via electroporation and then tumor-specific T cell epitopes are presented to T cells. Indirect presentation stimulates non-APCs to produce the antibody protein which targets the APC via the antibody’s Fc receptor. This stimulation of the APC through multiple pathways amplifies the immune response and produces larger quantities of high-avidity T-cells that can reduce tumor size.